Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to -$92.7 million.

  • Ultragenyx Pharmaceutical's Free Cash Flow fell 3510.9% to -$92.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$451.4 million, marking a year-over-year decrease of 570.55%. This contributed to the annual value of -$421.7 million for FY2024, which is 1876.31% up from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Free Cash Flow stood at -$92.7 million for Q3 2025, which was down 3510.9% from -$110.5 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's Free Cash Flow's 5-year high stood at -$68.6 million during Q3 2024, with a 5-year trough of -$193.9 million in Q1 2024.
  • Moreover, its 5-year median value for Free Cash Flow was -$110.5 million (2025), whereas its average is -$116.9 million.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Free Cash Flow tumbled by 20259.28% in 2021 and then surged by 4356.13% in 2024.
  • Ultragenyx Pharmaceutical's Free Cash Flow (Quarter) stood at -$70.4 million in 2021, then tumbled by 66.66% to -$117.3 million in 2022, then increased by 27.11% to -$85.5 million in 2023, then increased by 6.25% to -$80.2 million in 2024, then dropped by 15.65% to -$92.7 million in 2025.
  • Its last three reported values are -$92.7 million in Q3 2025, -$110.5 million for Q2 2025, and -$168.0 million during Q1 2025.